Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status
ACN Newswire
*TOKYO and CAMBRIDGE, Mass., May 15, 2024 - (JCN Newswire) - *Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that..